Department of Vascular Surgery, University Hospital Zurich, Zurich, Switzerland.
Department of Vascular Surgery, University Hospital Zurich, Zurich, Switzerland.
J Vasc Surg. 2022 Mar;75(3):813-823.e1. doi: 10.1016/j.jvs.2021.09.020. Epub 2021 Oct 2.
We evaluated the long-term morphologic and clinical outcomes after thoracic endovascular aortic repair combined with parallel grafts (PG-TEVAR) for arch-involving aortic pathologies.
We performed a retrospective analysis of perioperative and follow-up data of patients who had undergone PG-TEVAR at a single vascular surgery center from November 2010 to April 2018. Patients with prior or simultaneous open chest or cervical debranching procedures or arch repair were excluded. The primary endpoint was freedom from overall PG-TEVAR-related reintervention. The secondary endpoints were parallel graft sealing zone failure (presence of gutter-related type I or Ic endoleak), PG failure (occlusion or reintervention), stroke, and 30-day and overall PG-TEVAR-related and all-cause mortality. Kaplan-Meier curves were used to estimate the freedom from reintervention and survival. Receiver operating characteristics curves were used to find the optimal cutoff to prevent type Ia endoleak-related reintervention.
A total of 33 patients, including 8 women, with a median age of 74 years (interquartile range, 67-79 years) had undergone PG-TEVAR (chimney, periscope, and sandwich in 20, 15, and 13 patients, respectively) with proximal landing in Ishimaru zone 0, 1, or 2 in 4, 5, and 24 patients, respectively. The aortic pathologies included type B aortic dissection (acute and chronic, eight and six, respectively), degenerative aneurysm (n = 10), type Ia endoleak (n = 3), para-anastomotic/patch aneurysm (n = 4), left subclavian artery aneurysm (n = 1), and traumatic rupture (n = 1). The perioperative stroke rate and 30-day mortality was 6% and 9%, respectively. Direct postoperative computed tomography revealed 28 endoleaks (gutter-related type Ia, 12; gutter-related type Ib, 9; type Ia, 2; type Ic, 2; type III, 1; undetermined, 2) in 27 patients. The technical and clinical success rate was 37% and 30%, respectively. The mean follow-up for survival was 48 ± 31 months. The latest radiologic follow-up demonstrated 12 remaining and 1 new endoleak. The early and overall PG sealing zone failure and PG failure was 73% and 36% and 9% and 18%, respectively. The overall PG-TEVAR-related reintervention rate was 33% (n = 11). The estimated freedom from overall PG-TEVAR-related reintervention was 68% at 60 months. The main graft oversizing and length oversizing rates were not significantly associated statistically with the type Ia endoleak-related reintervention rate. The PG-TEVAR-related and all-cause mortality were 18% and 34%, respectively.
PG-TEVAR for total endovascular repair of arch-involving aortic pathologies resulted in a high rate of type I endoleaks and the need for long-term reintervention. Gutter-related endoleaks might be more frequent than reported and should not be underestimated because they can lead to sac enlargement and reintervention. Frequent radiologic surveillance is mandatory. Further studies comparing PG-TEVAR to other total endovascular alternatives are required to confirm these findings.
我们评估了胸主动脉腔内修复术(TEVAR)联合平行移植物(PG-TEVAR)治疗主动脉弓受累病变的长期形态学和临床结果。
我们对 2010 年 11 月至 2018 年 4 月期间在一家血管外科中心接受 PG-TEVAR 的患者的围手术期和随访数据进行了回顾性分析。排除了先前或同期开胸或颈动脉去分支术或弓部修复的患者。主要终点是无总体 PG-TEVAR 相关再干预。次要终点是平行移植物密封区失败(存在沟相关 I 型或 Ic 内漏)、PG 失败(闭塞或再干预)、卒中和 30 天及总体 PG-TEVAR 相关和全因死亡率。Kaplan-Meier 曲线用于估计无再干预和生存的概率。受试者工作特征曲线用于确定预防 I 型内漏相关再干预的最佳截断值。
共 33 例患者(8 例女性),中位年龄 74 岁(四分位距 67-79 岁),接受了 PG-TEVAR(烟囱、潜望镜和三明治分别在 20、15 和 13 例患者中使用),近端在 Ishimaru 0、1 或 2 区着陆的患者分别有 4、5 和 24 例。主动脉病变包括 B 型主动脉夹层(急性和慢性,分别为 8 例和 6 例)、退行性动脉瘤(n=10)、I 型内漏(n=3)、吻合口/补丁动脉瘤(n=4)、左锁骨下动脉动脉瘤(n=1)和创伤性破裂(n=1)。围手术期卒中发生率和 30 天死亡率分别为 6%和 9%。直接术后计算机断层扫描显示 27 例患者中有 28 例内漏(沟相关 I 型,12 例;沟相关 Ib 型,9 例;I 型,2 例;Ic 型,2 例;III 型,1 例;未确定,2 例)。技术和临床成功率分别为 37%和 30%。生存的平均随访时间为 48±31 个月。最新的影像学随访显示 12 例仍有内漏,1 例新发生内漏。早期和总体 PG 密封区失败和 PG 失败率分别为 73%和 36%,9%和 18%。总体 PG-TEVAR 相关再干预率为 33%(n=11)。估计 60 个月时总体 PG-TEVAR 相关再干预的无失败率为 68%。主要移植物过度扩张和长度过度扩张率与 I 型内漏相关再干预率无统计学显著相关性。PG-TEVAR 相关和全因死亡率分别为 18%和 34%。
PG-TEVAR 用于主动脉弓受累病变的完全血管内修复,导致 I 型内漏发生率高,需要长期再干预。沟相关内漏可能比报道的更常见,不应低估,因为它们会导致囊腔增大和再干预。必须进行频繁的影像学监测。需要进一步的研究比较 PG-TEVAR 与其他完全血管内替代方法,以证实这些发现。